Ken Griffin Larimar Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$6.3 - $10.68 $170,730 - $289,428	27,100 Added 1178.26%	29,400 $192,000
Q2 2024 Aug 14, 2024	SELL	$6.33 - $9.89 $100,647 - $157,251	-15,900 Reduced 87.36%	2,300 $16,000
Q1 2024 May 15, 2024	BUY	$4.2 - $13.28 $75,600 - $239,040	18,000 Added 9000.0%	18,200 $138,000
Q4 2023 Feb 14, 2024	SELL	$2.35 - $4.71 $1,175 - $2,355	-500 Reduced 71.43%	200 $0
Q3 2023 Nov 14, 2023	SELL	$3.08 - $4.49 $2,156 - $3,143	-700 Reduced 50.0%	700 $2,000
Q2 2023 Aug 14, 2023	BUY	$3.13 - $5.27 $2,191 - $3,688	700 Added 100.0%	1,400 $4,000
Q1 2023 May 15, 2023	BUY	$4.0 - $6.68 $2,800 - $4,676	700 New	700 $3,000

128

67.3M

280K

76.3K

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $171M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.